DPhil University of Oxford (PhD Cancer Research) MBBS (Hons 1) & BA University of Sydney

Dr Copeman is ConnectGene's oncology specialist. He has been involved in cancer research and treatment since 1985. He studied medicine at the University of Sydney, and then completed a doctorate in cancer research at the University of Oxford. Dr Copeman trained first in children's cancer care, and then moved into adult cancer research and treatment.

dr michael copeman

Experience &

Since 2000 Dr Copeman has lectured on new cancer medicines in 90 cities, across 30 countries around the world. He has provided advice about the development of new medicines to many of the world’s major pharmaceutical companies. Dr Copeman also operates The Copeman Clinic in Sydney, Australia, which aims to bring new tests and treatments for cancer to patients. He admits patients to Arcadia Hospital Warriewood and Manly Waters Private Hospital in Sydney.

Dr Copeman is a member of the Clinical Oncological Society of Australia, the American Societies of Clinical Oncology and of Haematology and the American Society of Paediatric Haematology / Oncology. He is a Fellow of the Royal Australasian College of Physicians.

Dr Copeman’s philosophy is that the patient comes first:

  • First in considering which tests to have;
  • First in considering what treatments to pursue; and
  • First in deciding where and how they want their care provided.

rcsi cosoa

aspho asco

Our Team

oncology doctor

Stephen Copeman
Managing Director

As Managing Director, Stephen oversees operations to ensure patients receive the highest levels of care when choosing to undertake their cancer treatment with ConnectGene Care. Based in Hong Kong since 2011, he has developed a thorough understanding of the dynamic changes occurring in the region, including in healthcare and technology. A finance professional by background, he has been involved in assisting companies establish operations in the region, and advised global corporate and financial institutions operating across Greater China.

oncologist australia

Arthur Fang

Arthur is ConnectGene’s regional Director. Fluent in English, Cantonese and Mandarin, he assists with building and coordinating our network of treatment providers and medical specialists. A Speech-Language Pathologist by training, he has been running his Hong Kong based clinic since 2012 which provides services to people with speech, language, social communication, and literacy issues. Outside the clinic, he lectures at the Education University of Hong Kong on Phonetics and Phonology, and Speech-Sound Disorder.

Our Industry Advisory Services

ConnectGene care can be engaged in a number of ways to advise healthcare practitioners and companies on developing cancer treatments and the application of genomic testing. As a specialist practice, our goal is to provide you with professional, comprehensive and timely services. We can help you with:

oncology specialist


If standard treatment protocols are not achieving the outcome desired, a referral to ConnectGene for a second opinion may assist in finding alternative treatments. In full consultation with you as the referring doctor, we can assess the need to utilise genomic testing to further understand your patient’s condition and pathways for treatment.


Advice for

ConnectGene can be engaged to advise you and your medical practice on developments in the treatment of cancer and the application of genomic testing, to help ensure the best possible outcomes for your patients. This may be patient specific, or general training for the healthcare practitioners in your clinic.

dr michael copeman

Consulting Services for Bio-Tech & Healthcare Companies

We research and monitor global developments in the treatment of cancer, including the impact of genomic testing on patient outcomes and treatment selection. We can provide advice on the latest developments in cancer research and clinical trials, so you can understand and integrate them into your treatment protocols.

oncology doctor

& Training

Since 2000 Dr Copeman has lectured on new cancer medicines in 90 cities, across 30 countries around the world, providing advice about the development of new medicines to many of the world’s major pharmaceutical companies.



Click one of our representatives below to chat on WhatsApp!